Jin YX, Hu HQ, Zhang JC, Xin XY, Zhu YT, Ye Y, Li D. Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions. World J Stem Cells 2024; 16(9): 842-845 [PMID: 39351263 DOI: 10.4252/wjsc.v16.i9.842]
Corresponding Author of This Article
Yang Ye, PhD, Research Assistant, Department of Traditional Chinese Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China. yeyang89@bjmu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Sep 26, 2024; 16(9): 842-845 Published online Sep 26, 2024. doi: 10.4252/wjsc.v16.i9.842
Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions
Yu-Xin Jin, Hang-Qi Hu, Jia-Cheng Zhang, Xi-Yan Xin, Yu-Tian Zhu, Yang Ye, Dong Li
Yu-Xin Jin, Hang-Qi Hu, Jia-Cheng Zhang, Xi-Yan Xin, Yu-Tian Zhu, Yang Ye, Dong Li, Department of Traditional Chinese Medicine, Peking University Third Hospital, Beijing 100191, China
Co-corresponding authors: Yang Ye and Dong Li.
Author contributions: Jin YX wrote the first draft of the manuscript; Hu HQ, Zhang JC, Xin XY, and Zhu YT contributed to review and editing; Ye Y and Li D conceived, reviewed, and revised this paper. Ye Y and Li D contributed equally and share the corresponding authorship.
Supported bySpecial Fund of the Beijing Clinical Key Specialty Construction Program, No. BJZKBC0011; and Clinical Key Project of Peking University Third Hospital, No. BYSYZD2023049.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yang Ye, PhD, Research Assistant, Department of Traditional Chinese Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China. yeyang89@bjmu.edu.cn
Received: July 13, 2024 Revised: August 8, 2024 Accepted: August 26, 2024 Published online: September 26, 2024 Processing time: 72 Days and 23.4 Hours
Abstract
Mesenchymal stem cells (MSCs) are a prevalent source for stem cell therapy and play a crucial role in modulating both innate and adaptive immune responses. Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of triglycerides in liver cells and involves immune system activation, leading to histological changes, tissue damage, and clinical symptoms. A recent publication by Jiang et al, highlighted the potential of MSCs to mitigate in NAFLD progression by targeting various molecular pathways, including glycolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. In this editorial, we comment on their research and discuss the efficacy of MSC therapy in treating NAFLD.
Core Tip: This editorial discusses a recent article published in the World Journal of Stem Cells, which presents mesenchymal stem cells as a promising therapeutic approach for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. The study emphasizes targeting key molecular pathways such as glycolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. We provide insights into their findings and explore relevant topics in this field.
